GLSI vs. ANAB, KURA, CRMD, ABUS, PHAR, IMTX, ORIC, RAPP, SEPN, and PGEN
Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include AnaptysBio (ANAB), Kura Oncology (KURA), CorMedix (CRMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Septerna (SEPN), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry.
Greenwich LifeSciences vs.
Greenwich LifeSciences (NASDAQ:GLSI) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.
In the previous week, AnaptysBio had 3 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 8 mentions for AnaptysBio and 5 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.21 beat AnaptysBio's score of 0.25 indicating that Greenwich LifeSciences is being referred to more favorably in the media.
Greenwich LifeSciences currently has a consensus price target of $38.00, suggesting a potential upside of 217.99%. AnaptysBio has a consensus price target of $36.20, suggesting a potential upside of 94.44%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than AnaptysBio.
Greenwich LifeSciences has a net margin of 0.00% compared to AnaptysBio's net margin of -289.75%. Greenwich LifeSciences' return on equity of -185.12% beat AnaptysBio's return on equity.
Greenwich LifeSciences has higher earnings, but lower revenue than AnaptysBio. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.
AnaptysBio received 364 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 66.19% of users gave AnaptysBio an outperform vote while only 44.44% of users gave Greenwich LifeSciences an outperform vote.
4.2% of Greenwich LifeSciences shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 33.7% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Greenwich LifeSciences beats AnaptysBio on 9 of the 17 factors compared between the two stocks.
Get Greenwich LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Greenwich LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:GLSI) was last updated on 2/22/2025 by MarketBeat.com Staff
